Felzartamab vs Sanritatug

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: CD38 · full Multiple Myeloma pipeline

Felzartamab

Developed by Biogen and partners

Phase 3 in Multiple Myelomamonoclonal antibody
Partial signal

NCT03952091 · Phase 3 · completed

This was a large (n=289), randomized, active-controlled Phase 3 trial using a well-accepted hard clinical endpoint (progression-free survival), and the drug combination showed a statistically significant improvement over the active comparator. However, the trial was conducted completely open-label with no blinding of patients or investigators, which limits confidence in the result despite its objective endpoint and statistical significance.

Reported efficacy

Progression-free survival (PFS) (18.4 months(Active) 30.7 months(experimental)): Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035) (met)

Result source: NCT03952091

Sanritatug

Developed by Hangzhou Sumgen Biotech Co., Ltd.

Phase 3 in Multiple Myelomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT06508983 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFelzartamabSanritatug
PFS, median—Not posted · NCT03952091—Trial running · NCT06508983
OS, median—Not posted · NCT03952091—Trial running · NCT06508983
ORR—Not posted · NCT03952091—Trial running · NCT06508983
VGPR or better—Not posted · NCT03952091—Trial running · NCT06508983
MRD negativity—Not posted · NCT03952091—Trial running · NCT06508983

PFS, median

Felzartamab
—Not posted · NCT03952091
Sanritatug
—Trial running · NCT06508983

OS, median

Felzartamab
—Not posted · NCT03952091
Sanritatug
—Trial running · NCT06508983

ORR

Felzartamab
—Not posted · NCT03952091
Sanritatug
—Trial running · NCT06508983

VGPR or better

Felzartamab
—Not posted · NCT03952091
Sanritatug
—Trial running · NCT06508983

MRD negativity

Felzartamab
—Not posted · NCT03952091
Sanritatug
—Trial running · NCT06508983
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Sanritatug: no structured comparison results are available for Multiple Myeloma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Felzartamab
Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035) NCT03952091 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Felzartamab's landscape · Sanritatug's landscape